Long intergenic noncoding RNA 00641 inhibits breast cancer cell proliferation, migration, and invasion by sponging miR‐194‐5p

Mao, Qixin; Lv, Minhao; Li, Lianfang; Sun, Yan; Liu, Shanqing; Shen, Yan; Liu, Zhenzhen; Luo, Suxia

doi:10.1002/jcp.29170

Cited by 31 publications

(31 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…SNHG18 promotes resistance of glioma to radiotherapy by repressing semaphorin 5A [45]. LINC00641 expression level was found to be decreased in breast cancer tissue, which was negatively related to tumor size, lymph node metastasis, and clinical stage [46]. SNAI3-AS1 could bond up-frameshift protein 1 (UPF1), regulate Smad7 expression, and activate TGF-β/Smad pathway, to induce EMT in hepatocellular carcinoma [47], and it also acts an important factor in the ceRNA network in Adipose Tissue From Type 2…”

Section: Discussionmentioning

confidence: 93%

Identification of an EMT-related lncRNA signature in glioma

Tao

Luo

et al. 2020

Preprint

View full text Add to dashboard Cite

Background Epithelial-mesenchymal transition (EMT) has been implicated in the invasion and progression of gliomas, the present study investigated EMT-related long noncoding (lnc)RNAs in gliomas.Methods Candidate lncRNAs screened from a glioma dataset in The Cancer Genome Atlas were used to construct EMT-related lncRNA coexpression networks in order to identify EMT-related lncRNAs; these were validated using the Chinese Glioma Genome Atlas (CGGA). Gene set enrichment analysis and principal component analysis (PCA) were used to annotate lncRNA functions. We established an EMT-related lncRNA signature composed of 9 lncRNAs (HAR1A, LINC00641, LINC00900, MIR210HG, MIR22HG, PVT1, SLC25A21-AS1, SNAI3-AS1, and SNHG18) that could distinguish between low- and high-risk glioma patients. The functions of the identified lncRNAs were evaluated by constructing a competing endogenous RNA network.Results The low-risk group had longer overall survival (OS) than the high-risk group (P<0.0001). High-risk patients also had no deletion on chromosome arms 1p and/or 19q, expressed wild-type isocitrate dehydrogenase, and had higher World Health Organization (WHO) tumor grade. The signature was an independent factor significantly associated with OS (P=0.041, hazard ratio=1.806). These findings were validated in the CGGA dataset. PCA also revealed differences in EMT status between low- and high-risk patients. Competing endogenous RNA network showed that complex lncRNA–microRNA–mRNA interactions potentially contributing to EMT progression in glioma. Conclusion Our results demonstrate that the EMT-related 9-lncRNA signature has prognostic value for glioma patients.

show abstract

Section: Discussionmentioning

confidence: 93%

Identification of an EMT-related lncRNA signature in glioma

Tao

Luo

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…Previous studies have shown that LINC00461 that serves as competitive endogenous RNA of microRNA-942 could affect the survival of patients with renal cell carcinoma (23). As for breast cancer, the expression level of LINC00641 was negatively correlated with the size of tumor, lymph node metastasis, and clinical stage, which could restrain the proliferation and migration of breast cancer cells (24). lncRNA DGCR9 was up-regulated in gastric cancer tissues, which played the role of promoting cell proliferation, migration and glucose metabolism, and of great importance for the progress of gastric cancer (25).…”

Section: Discussionmentioning

confidence: 98%

Identification and Verification on Prognostic Index of Lower-Grade Glioma Immune-Related LncRNAs

Wen

Wang

et al. 2020

Front. Oncol.

View full text Add to dashboard Cite

Previous studies have shown that the prognosis of patients with lower-grade glioma (LGG) is closely related to the infiltration of immune cells and the expression of long non-coding RNAs (lncRNAs). In this paper, we applied single-sample gene set enrichment analysis (ssGSEA) algorithm to evaluate the expression level of immune genes from tumor tissues in The Cancer Genome Atlas (TCGA) database, and divided patients into the high immune group and the low immune group, which were separately analyzed for differential expression. Venn analysis was taken to select 36 immune-related lncRNAs. To construct a prognostic model of LGG based on immune-related lncRNAs, we divided patients into a training set and a verification set at a ratio of 2:1. Univariate Cox regression and the Least Absolute Shrinkage and Selection Operator (LASSO) regression were performed to select 11 immune-related lncRNAs associated with the prognosis of LGG, and based on these selected lncRNAs, the risk scoring model was constructed. Through Kaplan-Meier analysis, the overall survival (OS) of patients in the high-risk group was significantly lower than that of the low-risk group. Then, established a nomogram including age, gender, neoplasm histologic grade, and risk score. Meanwhile, the predictive performance of the model was evaluated by calculating the C-index, drawing the calibration chart, the clinical decision curve as well as the Receiver Operating Characteristic (ROC) curve. Similar results were obtained by utilizing the validation data to verify the above consequences. Based on the TIMER database, the correlation analysis showed that the 11 immune-related lncRNAs risk score of LGG were in connection with the infiltration of the subtypes of immune cells. Subsequently, we performed enrichment analysis, whose results showed that these immune-related lncRNAs played important roles in the progress of LGG. In conclusion, these 11 immune-related lncRNAs have the potential to predict the prognosis of patients with LGG, which may play a key role in the development of LGG.

show abstract

“…As far as BC is concerned, the inhibition of miR-194-5p in MCF7 cells was shown to correlate with decreased proliferation, migration and tumor growth [ 69 ], while in HER2 overexpressing BCCs, miR-194 knockdown promoted cancer cell migration and invasion [ 70 ]. Mao et al reported that the overexpression of miR-194-5p in both MCF7 and MDA-MB-231 cells promoted BCC proliferation, migration and invasion, while repressing cell death [ 71 ]. In accordance, in our in vitro system, 4T1 cells alone and in mixed culture, released and expressed miR-194-5p, especially in ‘metastasis-like’ clusters, being particularly evident in more marginal, possibly more invasive/migratory cells.…”

Section: Discussionmentioning

confidence: 99%

MicroRNAs and Extracellular Vesicles as Distinctive Biomarkers of Precocious and Advanced Stages of Breast Cancer Brain Metastases Development

Figueira

Godinho-Pereira

Galego

et al. 2021

IJMS

View full text Add to dashboard Cite

Triple negative breast cancer presents higher mortality and poorer survival rates than other breast cancer (BC) types, due to the proneness to brain metastases formation, which are usually diagnosed at advanced stages. Therefore, the discovery of BC brain metastases (BCBM) biomarkers appears pivotal for a timely intervention. With this work, we aimed to disclose microRNAs (miRNAs) and extracellular vesicles (EVs) in the circulation as biomarkers of BCBM formation. Using a BCBM animal model, we analyzed EVs in plasma by nanoparticle tracking analysis and ascertained their blood-brain barrier (BBB) origin by flow cytometry. We further evaluated circulating miRNAs by RT-qPCR and their brain expression by in situ hybridization. In parallel, a cellular model of BCBM formation, combining triple negative BC cells and BBB endothelial cells, was used to differentiate the origin of biomarkers. Established metastases were associated with an increased content of circulating EVs, particularly of BBB origin. Interestingly, deregulated miRNAs in the circulation were observed prior to BCBM detection, and their brain origin was suggested by matching alterations in brain parenchyma. In vitro studies indicated that miR-194-5p and miR-205-5p are expressed and released by BC cells, endothelial cells and during their interaction. These results highlight miRNAs and EVs as biomarkers of BCBM in early and advanced stages, respectively.

show abstract

Long intergenic noncoding RNA 00641 inhibits breast cancer cell proliferation, migration, and invasion by sponging miR‐194‐5p

Cited by 31 publications

References 18 publications

Identification of an EMT-related lncRNA signature in glioma

Identification of an EMT-related lncRNA signature in glioma

Identification and Verification on Prognostic Index of Lower-Grade Glioma Immune-Related LncRNAs

MicroRNAs and Extracellular Vesicles as Distinctive Biomarkers of Precocious and Advanced Stages of Breast Cancer Brain Metastases Development

Contact Info

Product

Resources

About